» Articles » PMID: 27782066

Boosting Tumor-Specific Immunity Using PDT

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2016 Oct 27
PMID 27782066
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic therapy (PDT) is a cancer treatment with a long-standing history. It employs the application of nontoxic components, namely a light-sensitive photosensitizer and visible light, to generate reactive oxygen species (ROS). These ROS lead to tumor cell destruction, which is accompanied by the induction of an acute inflammatory response. This inflammatory process sends a danger signal to the innate immune system, which results in activation of specific cell types and release of additional inflammatory mediators. Activation of the innate immune response is necessary for subsequent induction of the adaptive arm of the immune system. This includes the priming of tumor-specific cytotoxic T lymphocytes (CTL) that have the capability to directly recognize and kill cells which display an altered self. The past decades have brought increasing appreciation for the importance of the generation of an adaptive immune response for long-term tumor control and induction of immune memory to combat recurrent disease. This has led to considerable effort to elucidate the immune effects PDT treatment elicits. In this review we deal with the progress which has been made during the past 20 years in uncovering the role of PDT in the induction of the tumor-specific immune response, with special emphasis on adaptive immunity.

Citing Articles

Direct and Abscopal Antitumor Responses Elicited by AlPcNE-Mediated Photodynamic Therapy in a Murine Melanoma Model.

Morais J, Barros P, Brigido M, Marina C, Bocca A, Mariano A Pharmaceutics. 2024; 16(9).

PMID: 39339213 PMC: 11435272. DOI: 10.3390/pharmaceutics16091177.


Recent Progress in Photothermal, Photodynamic and Sonodynamic Cancer Therapy: Through the cGAS-STING Pathway to Efficacy-Enhancing Strategies.

Fang K, Zhang H, Kong Q, Ma Y, Xiong T, Qin T Molecules. 2024; 29(15).

PMID: 39125107 PMC: 11314065. DOI: 10.3390/molecules29153704.


Photodynamic therapy upregulates expression of HIF-1α and PD-L1 in related pathways and its clinical relevance in non-small-cell lung cancer.

Sun W, Cheng Y, Ma X, Jin Z, Zhang Q, Wang G Eur J Med Res. 2024; 29(1):230.

PMID: 38609977 PMC: 11015541. DOI: 10.1186/s40001-024-01780-0.


Photodynamic Therapy and Adaptive Immunity Induced by Reactive Oxygen Species: Recent Reports.

Aebisher D, Woznicki P, Bartusik-Aebisher D Cancers (Basel). 2024; 16(5).

PMID: 38473328 PMC: 10930503. DOI: 10.3390/cancers16050967.


ROS regulation in gliomas: implications for treatment strategies.

Yang Y, Zhu Y, Sun S, Zhao C, Bai Y, Wang J Front Immunol. 2023; 14:1259797.

PMID: 38130720 PMC: 10733468. DOI: 10.3389/fimmu.2023.1259797.


References
1.
Bechet D, Mordon S, Guillemin F, Barberi-Heyob M . Photodynamic therapy of malignant brain tumours: a complementary approach to conventional therapies. Cancer Treat Rev. 2012; 40(2):229-41. DOI: 10.1016/j.ctrv.2012.07.004. View

2.
Zhou L, Lopes J, Chong M, Ivanov I, Min R, Victora G . TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008; 453(7192):236-40. PMC: 2597437. DOI: 10.1038/nature06878. View

3.
Knutson K, Disis M . Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005; 54(8):721-8. PMC: 11032889. DOI: 10.1007/s00262-004-0653-2. View

4.
Kalia V, Penny L, Yuzefpolskiy Y, Baumann F, Sarkar S . Quiescence of Memory CD8(+) T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4. Immunity. 2015; 42(6):1116-29. DOI: 10.1016/j.immuni.2015.05.023. View

5.
Chen M, Pittet M, Gorelik L, Flavell R, Weissleder R, von Boehmer H . Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2004; 102(2):419-24. PMC: 544311. DOI: 10.1073/pnas.0408197102. View